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This study was undertaken to evaluate the eﬀect of oral administration of lactoferrin (LF) and lactoperoxidase-(LPO-)containing
tablet on periodontal condition. Seventy-two individuals with chronic periodontitis were randomly assigned to take either bovine
LF and LPO-containing tablets (test group, n = 37) or control tablets (control group, n = 35) every day for 12 weeks. Periodontal
parameters and levels of subgingival plaque bacteria, human and bovine LF, and endotoxin in gingival crevicular ﬂuid (GCF) were
evaluated at baseline, 1 week, 4 weeks, and 12 weeks. Signiﬁcant diﬀerences were observed in GCF levels of bovine LF between the
test and control groups throughout the study (P<. 05). However, clinical and bacteriological parameter values proved comparable
between the two groups at 1 week to 12 weeks. Therefore, the eﬀect of oral administration of LF and LPO-containing tablets might
be weak on periodontal and bacteriological proﬁle in this study.
1.Introduction
One of the essential components of therapy for periodon-
tal diseases is elimination or control of periodontopathic
bacteria. This has been accomplished predominantly by
mechanical strategies including oral hygiene techniques and
scaling/root plaining [1], occasionally being time consuming
and ineﬀective in sites with diﬃculties of instrumentation
[2]. Therefore, a variety of locally delivered antibacterial
agents have been recommended as an adjunct method
[3, 4]. However, these antibacterial agents were shown to
originate some local side eﬀects [3, 5], suggesting the need
for antiinfective products to be used more safely.
Lactoferrin (LF) is an 80-kDa iron-binding glycoprotein
of the transferrin family and is a component of saliva as well
as milk, tears, and secondary granules of neutrophils [6]. LF
has been shown to have a diverse range of biological prop-
erties, for example, antibacterial, antiviral, and antioxidant
activities[7,8].IthasalsobeendemonstratedthatLFshowed
an in vitro antibacterial activity against periodontopathic
bacteria,includingPorphyromonas gingivalis,Prevotellainter-
media, and Aggregatibacter actinomycetemcomitans [9–12].
Especially, the growth of P. gingivalis was strongly inhibited
evenwithalowconcentration(13.6μM)ofLF[12].Recently,
our in vitro study indicated the inhibitory eﬀects of bovine
LF on bioﬁlm formation of P. gingivalis and P. intermedia
[13]. We also demonstrated that oral administration of
bovine LF reduced the number of these periodontopathic
bacteria in subgingival plaque of periodontitis patients [14].
Lactoperoxidase (LPO) is a member of the mammalian
heme peroxidase family and is a component of saliva, milk,
tears, and other exocrine secretions [15]. LPO catalyzes the2 International Journal of Dentistry
hydrogen peroxide-dependent oxidation of thiocyanate to
hypothiocyanate, exhibiting antimicrobial properties [15]. It
has also been documented that growth and viability of oral
bacteria were reduced by LPO thicyanate-hydrogen peroxide
system [16, 17].
Recently, LF and LPO-containing tablets were shown
to exhibit a possible inhibitory eﬀect on bacteria in
saliva and oral malodor [18]. Therefore, we conducted a
double-blinded, randomized, controlled trial in periodonti-
tis patients to evaluate the eﬃcacy of LF and LPO-containing
tablets on periodontal parameters, and levels of subgingival
plaque bacteria, and bovine and human LF, and endotoxin in
gingival crevicular ﬂuid (GCF).
2. Methods
2.1. Subjects and Clinical Assessments. At o t a lo fs e v e n t y -
six individuals who had been referred to Shimizu Dental
Clinic were recruited between October 2008 and July 2009
for this study. Signed informed consent was obtained from
all participants; the format of the study was reviewed and
approved by the Research Ethics Committee of Niigata Uni-
versity Faculty of Dentistry (no. 20-R23-08-08, on August
25, 2008) in accordance with the Helsinki Declaration of
1975andasrevisedin2000.Clinicalperiodontalassessments
were performed by one trained and calibrated examiner
of the authors (E. S.) who were masked to the group
assignments. The calibration was performedbefore the study
with 5 volunteer subjects in Niigata University Faculty of
Dentistry. The reproducibility of the clinical measurements
was calculated by means of the κ index, and a value of 0.857
was obtained for clinical attachment level (CAL) with a dif-
ference of ±1mm. All participants were clinically evaluated
in the following periodontal measurements: number of teeth
present, plaque index (PlI) [19], gingival index (GI) [20],
probing depth (PD),CAL, plaquecontrolrecord(PCR)[21],
and bleeding on probing (BOP) [22]. PlI, GI, BOP, and PCR
were measured at four sites around each tooth, whereas PD
and CAL were assessed using a CP-12 probe (Hu-Friedy,
Chicago, IL) at six sites around each tooth: mesio-buccal,
mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and
disto-lingual. Measurements of PD were recorded to the
nearest millimeter, and every observation close to 0.5mm
was rounded to the lower whole number. The mean value
of each clinical parameter for each individual was used for
the statistical analysis. The medical and dental records as
well as smoking status of all participants were also checked
with a standard questionnaire. Two subjects were excluded
from this study according to the following exclusion criteria:
(1) the presence of systemic disease (e.g., diabetes mellitus,
kidney, liver, or lung disease), medication, and pregnancy,
(2) having less than 20 teeth, (3) showing allergic reactions
to cow’s milk, (4) having antibiotic treatment within the
previous 3 months, (5) having periodontal therapy within
the previous 6 months, and (6) the current smoker. As a
result, seventy-four subjects (33 males and 41 females, age
range 32–73 years) with chronic periodontitis were selected
for this study.
2.2. Study Tablets. The test tablet (Morinaga Milk Industry
Co., Ltd., Tokyo, Japan) contained 11.1% (weight/weight)
LF, 0.2% LPO, 2.7% glucose oxidase, 3.0% glucose, 3.5%
trisodium citrate dehydrate, 1.6% citric acid, 30.0% ery-
thritol, 7.5% xylitol, 36.0% maltitol, 0.3% ﬂavor, 0.2% l-
menthol, 2.0% sucrose fatty acid ester, and 2.0% glycerol
fatty acid ester. The composition of the control tablet
(Morinaga Milk Industry Co., Ltd., Tokyo, Japan) was
83.9% maltitol, 11.1% cornstarch, 0.5% coloring mate-
rials, 0.3% ﬂavor, 0.2% l-menthol, 2.0% sucrose fatty
acid ester, and 2.0% glycerol fatty acid ester. LF (Mori-
naga Milk Industry Co., Ltd., Tokyo, Japan) and LPO
(Biopole, Gembloux, Belgium) were puriﬁed from bovine
milk, whereas glucose oxidase (Sumizyme PGO, Shin-Nihon
Chemical, Aichi, Japan) was originated from Penicillium
chrysogenum. These test and control tablets were round in
shape with a 12-mm diameter and 6-mm thickness and
were also identical in weight (900mg), taste, texture, and
appearance.
2.3. Study Protocol. This study was performed as a double-
blinded, randomized, controlled design during 12 weeks
(12W). All individuals were randomly assigned to oral
administration of either one tablet containing bovine LF
(100.0mg/tab) and bovine LPO (1.8mg/tab) in the test
group (n = 38) or one control tablet in the control group
(n = 36), three times per day for 12W. An independent
study coordinator (Morinaga Milk Industry Co., Ltd., Tokyo,
Japan) generated a random allocation sequence using a
computer-generated random code and marked on packages
containing test or control tablets with the subject numbers.
The allocation sequence was concealed until interventions
werecompleted.A12-weekrationofthetestorcontroltablet
wasdistributedatbaseline.Allsubjectsweredirectedtoplace
one tablet in the oral cavity for 5 minutes after the main
meal,allowingittodissolve.Inaddition,theywereinstructed
not to change their oral hygiene regimens, not to take any
foods and drinks containing LF, and not to use mouthwash
and dentifrice containing LF and LPO throughout the
study period. Neither professional prophylaxis nor tooth-
brushing instruction was performed during and before the
experimental period. Periodontal clinical parameters and
samples of saliva, subgingival plaque, and gingival crevicular
ﬂuid (GCF) were obtained from all subjects on baseline,
1W, 4W, and 12W. On the examination day, all participants
underwent clinical assessment and sampling at the same
appointment time (10:00 to 11:00, 14:30 to 15:30, or 19:00 to
20:00), that is two or three hours later following main meal,
tooth-brushing, and the intake of tablet. General condition
was evaluated by interviewing at each time examination.
Teeth, oral mucosa, and tongue were also examined visually.
After the baseline examination, one subject in the control
group did not undergo any examinations at 1 to 12W,
and another subject in the test group was lost at 12W.
Finally, 72 subjects (37 in the test group and 35 in the
control group) were subjected to the clinical, bacteriological,
and biochemical analysis. The ﬂowchart of all partici-
pants through each stage of the clinical trial is shown in
Figure 1.International Journal of Dentistry 3
Applicants (n = 76)
Excluded (n = 2)
Randomized (n = 74)
A l l o c a t e dt ot e s tg r o u p
(n = 38)
Received allocated intervention
(n = 38)
Allocated to test group
(n = 36)
Received allocated intervention
(n = 36)
Lost to followup (n = 1) Lost to followup (n = 1)
Analyzed (n = 37)
Excluded from analysis (n = 0)
Analyzed (n = 35)
Excluded from analysis (n = 0)
Figure 1: Flowchart of participants through each stage of the
randomized trial.
2.4. Sample Collection. After clinical measurements, saliva,
subgingival plaque and GCF samples were obtained. Whole
salivawascollectedintosterile15-mlplastictubesbyparaﬃn
chewing stimulation for 5 minutes [23]. Aliquots were
made from saliva samples and stored at −20◦C until used.
Sampling sites of the selected diseased two teeth with a PD
of 4 to 9mm per subject were isolated with sterile cotton
rolls. Supragingival plaque was removed with sterile curettes,
without touching the marginal gingival. Subgingival plaque
samples were then taken by inserting two sterile #40 paper
points (DiaDent Group International, Burnaby, Canada)
consecutivelyintotheperiodontalpocketfor10seconds.The
paper points were placed in sterile 3.6-ml plastic tubes and
stored at −20◦C until extraction of genomic DNA. After 5
minutes later of completion of subgingival plaque sampling,
GCF was collected from the same sites with ﬁlter paper strips
(Periopaper, Proﬂow Incorporated, Amityville, NY) [24].
The strips were placed into the pocket until mild resistance
was sensed, and left in place for 30 seconds. Each strip
was vortexed vigorously in 1ml of 0.05M Tris-HCl buﬀer
(pH 7.5) containing 0.1% bovine serum albumin and 0.1%
sodium azide and was kept at 4◦C. The GCF sample was then
centrifuged at 3,000×g for 5 minutes, and the supernatant
was stored at −80◦C until assayed.
2.5. Microbiological Examination. A quantitative analysis of
P. gingivalis and the total bacteria was done with the Invader
PLUS method [25], which combines the polymerase chain
reaction ampliﬁcation and Invader detection. In brief, bacte-
rial DNA was extracted from the stored samples of saliva and
subgingival plaque using a DNA blood mini kit (QIAamp,
Qiagen, Hilden, Germany). The primers for P. gingivalis were
based on a region of the 16S ribosomal RNA sequences
asfollows:forwardprimer(5 -GCGCTCAACGTTCAGCCT-
3 ) reverse primer (5 -CACGAATTCCGCCTGCC-3 ). The
primary probe and Invader oligo were based on sequences
in the ampliﬁed regions as follows: primary probe (5 -CGC-
GCCGAGGGGCAGTTTCAACGGC-3 )a n dI n v a d e ro l i g o
(5 -GCCGCCGCTGAACTCAAGCCCT-3 ). Likewise, the
primers, probe and oligo for the total bacteria were designed
as follows: forward primer (5 -GGATTCGCTAGTAATCG-
3 )a n dr e v e r s ep r i m e r( 5  -TACCTTGTTACGACTT-3 ),
primary probe (5 -CGCGCCGAGGCCGGGAACGTATTC-
ACC-3 )a n dI n v a d e ro l i g o( 5  -TGACGGGCGGTGTGT-
ACAAGGCA-3 ), respectively. The Invader PLUS reaction
was performed in a 15-μl mixture containing speciﬁc
primers, 50μM deoxynucleotide triphosphate (d-NTP),
700nM primary probe, 70nM Invader oligo, 2.5U Taq
polymerase(AmpliTaqStoﬀelfragment,AppliedBiosystems,
Foster city, CA), and Cleavase XI Invader core reagent
kit (genomic DNA, TWT, Madison, WI). The reaction
mixture was preheated at 50◦C for 2 minutes, and two-step
polymerasechainreactionwascarriedoutfor35cycles(95◦C
for 1 second and 63◦C for 1 minute). Fluorescence values of
carboxyﬂuoresceinweremeasuredatawavelengthof 485nm
(excitation) and 530nm (emission). The limit of detection
was determined with dilutions of the bacterial DNA, and the
standard curves were made on the crossing point determined
by ﬁt point methods. The number of bacteria was calculated
from the standard curves and expressed as Log10 copies/ml
and Log10 copies/site for the saliva and subgingival plaque
sample, respectively. As the detection limit for the bacterial
count was 3Log10 (= 1000)/ml or site, the lowest value was
indicated as 1000 for the count of samples under the limit.
According to the detection limit, the number (percentage) of
saliva and subgingival plaque samples at baseline in which P.
gingivalis was detected proved 16 (43.2%) and 26 (35.1%) in
the test group, and 14 (40.0%) and 25 (35.7%) in the control
group, respectively. The quantitative analysis of P. gingivalis
and the total bacteria was performed three times in each
sample to conﬁrm the reproducibility of the outcomes.
2.6. Measurement of LF and Endotoxin Levels. The concen-
trations of bovine LF in the saliva and GCF samples were
determined by an sandwich enzyme-linked immunosorbent
assay (ELISA) with antibovine LF polyclonal antibody and
horseradish peroxide-conjugated antibovine LF antibody
(Bethyl Laboratories, Inc., Montgomery, TX). Levels of
human LF in the saliva and GCF samples were measured by
a sandwich ELISA assay with an antihuman LF polyclonal
antibody (Dakopatts, Glostrup, Denmark). The microtiter
plates were read at a wavelength of 405nm for both LF levels
with an automated microplate reader (MTP-32, Corona
Electric Co., Ltd., Hitachi, Japan). The concentration of
bovine and human LF was expressed as μg/ml for the
saliva sample and ng/site for the GCF sample, respectively.
Sensitivity of the bovine LF measurements was 10ng/ml and
those of the human LF measurements was 50ng/ml.
Saliva and GCF levels of endotoxin were measured by
the Limulus amebocyte lysate assay using a commercially
available kit (Endospecy ES-24S Set, Seikagaku Biobusiness
Corporation, Tokyo, Japan), according to the manufacturer’s
instruction. All reagents, pipette tips and microtiter plates
were pyrogen free. The coloriometric changes reﬂecting4 International Journal of Dentistry
Table 1: Demographic characteristics of participants.
Characteristics Test group Control
group P-value
Subjects (number) 37 35
Age (mean ± SD years) 52.5 ±11.85 1 .7 ±11.3. 7 1
Gender (number of
Female/Male) 12/25 15/20 .06
Smoking status .47
Current smoker (number) 0 0
Former smoker (number) 3 5
Never smoked (number) 34 30
Number of teeth examined∗ 74 70 .22
Anterior teeth (number) 5 10
Premolar teeth (number) 53 50
Molar teeth (number) 16 10
∗Two teeth with chronic periodontitis were examined per subject for
clinical, bacteriological and biochemical parameters.
Diﬀerences in age and gender between the two groups were assessed by
Mann-Whitney U test, and those in smoking status and the number of teeth
examined between the groups were evaluated by chi-square or Fisher’s exact
test, respectively.
endotoxin levels were measured at a wavelength of 540nm
using an automated microplate reader (MTP-32, Corona
Electric Co., Ltd., Hitachi, Japan). The concentration of
endotoxin was expressed as equivalent of USP standard
unit (EU)/ml and EU/site for the saliva and GCF sample,
respectively. The lower limit of detection was 0.002EU/ml.
Measurements of bovine and human LF and endotoxin
were performed three times in each sample to conﬁrm the
reproducibility of the outcomes.
2.7. Statistical Analyses. The post-hoc sample size esti-
mates/powercalculationtestwhichwasbasedonthenumber
of P. gingivalis in subgingival plaque revealed that more
than 26 patients in each of the two groups would meet
the statistical power, with the following assumptions: 5% of
alpha level, 0.81 of anticipated eﬀect size, 0.8 of statistical
power level, in two-tailed hypothesis. Diﬀerences between
the test and control groups in demographic and clinical
parameter values were assessed by Mann-Whitney U test,
and by chi-square or Fisher’s exact test for categorical
variables, while those in bacterial counts and levels of
endotoxinandLFwereevaluatedbyStudent’st-test.Theunit
of analysis was individual in demographic parameters (age,
gender, smoking status, and the number of teeth present),
PCR, the number of total bacteria and P. gingivalis in saliva,
saliva levels of bovine and human LF and endotoxin, while
that was site in PlI, GI, BOP, PD, CAL, the number of total
bacteria and P. gingivalis in subgingival plaque, and GCF
levels of bovine and human LF and endotoxin. All outcome
analyses were performed according to the intention-to-treat
principle. Statistical signiﬁcance was set at P<. 05.
3. Results
At baseline, we found no signiﬁcant diﬀerences in any demo-
graphic and clinical periodontal parameter values between
the test and control groups (Tables 1 and 2). Bovine LF levels
in saliva and GCF in the test group were signiﬁcantly higher
than those in the control group (P<. 05) (Figures 2(a) and
2(b)). However, no signiﬁcant diﬀerences were observed in
any clinical periodontal parameters at 1W to 12W between
the two groups (Table 2). Human LF levels in saliva and GCF
were also comparable between the two groups (Figures 2(c)
and 2(d)).
The number of total bacteria and P. gingivalis in
saliva and subgingival plaque was not signiﬁcantly diﬀerent
between the two groups (Figures 3(a) to 3(d)), with excep-
tion that a signiﬁcant intergroup diﬀerence in the number of
t o t a lb a c t e r i ai ns a l i v aa tb a s e l i n e( P<. 05). Endotoxin levels
also proved comparable between the two groups throughout
a 12W-observation period (Figures 3(e) and 3(f)).
General condition was obtained by interviewing subjects
at each time examination. No adverse events were observed
in all participants during the study period. One subject
in the control group was withdrawn at 1W, and another
subject in the test group was lost at 12W. These subjects
were also conﬁrmed to exhibit no general symptoms before
the withdrawal. Furthermore, abnormal eﬀects on teeth,
gingiva,oralmucosa,andtonguewerenotobservedonvisual
examination.
4. Discussion
In this clinical trial, a total of seventy-two participants
(37 in the test group and 35 in the control group) was
subjected to the clinical, bacteriological, and biochemical
analysis. Based on the reported changes in the number of
P. gingivalis in subgingival plaque in the test and control
groups ([mean ± SD]: 1.04 ± 1.72 and −0.20 ± 1.29
[log10/paperpoint] in our previous study [14], the number
of subjects needed per the group was calculated by post-
hoc sample size estimates/power calculation test, using the
following assumptions: 5% of alpha level, and 0.81 of
anticipated eﬀect size, 0.8 of statistical power level, in two-
tailed hypothesis. It was observed that more than 26 patients
in each of the two groups, when randomly allocated, would
meet the statistical power.
The results of this study failed to demonstrate an oral
administration of the test tablet containing bovine LF
and LPO to be eﬀective in improvements of clinical and
bacteriological parameter values, although the test group
showed a signiﬁcant reduction in change in PlI score at
1W, as compared to the control group (data not shown).
These results were diﬀerent from the ﬁndings of other
studies indicating an in vitro antibioﬁlm activity of bovine
LF [13], and antiinﬂammatory eﬀects of LF and LPO [26,
27]. These observations might be partly attributable to
insuﬃcient concentration of LF for the antibacterial activity.
The GCF concentrations of bovine LF in the test group were
calculated to be 1.8 to 3.2μg/ml, on the basis of assumption
that 2μl of GCF was obtained [24] .T h e s eL Fl e v e l sw e r e
shown to be under the concentration of 8 to 31μg/ml, at
which the antibioﬁlm activity of bovine LF proved eﬀective
against P. gingivalis [13]. Therefore, it is suggested that oral
administrationoftabletcontainingbovineLF(100.0mg/tab)International Journal of Dentistry 5
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Figure 2: Eﬀect of the test tablet on bovine and human LF levels in saliva and gingival crevicular ﬂuid (GCF). Saliva levels of bovine LF
(a), GCF levels of bovine LF (b), Saliva levels of human LF (c), and GCF levels of human LF (d) were measured at baseline, 1W, 4W, 12W.
Values represent the mean ± standard error. GCF levels of bovine and human LF were assessed in two teeth with chronic periodontitis per
subject. ∗Signiﬁcant diﬀerence between the test and control groups, as identiﬁed by Student’s t-test (P<. 05).
and bovine LPO (1.8mg/tab) in this study would neither
clearly inﬂuence the clinical periodontal condition nor the
number of bacteria in saliva and subgingival plaque. Recent
study documented that the same composition of bovine LF
and LPO showed little eﬀect on the numbers of some peri-
odontopathic bacteria in saliva by quantitative polymerase
chain reactions, which is in accordance with our results,
but terminal restriction fragment length polymorphism
(T-RFLP) detected one fragment with a signiﬁcant lower
number of the copy in the test group compared to that in the
control group [18]. Thus, comprehensive T-RFLP analysis
of bacteria in the plaque would be interesting in the future
study.
Both test and control groups showed a weak trend
toward a decrease in levels of periodontal inﬂammation
(GI and BOP) and destruction (PD and CAL) and in the
number of total bacteria and P. gingivalis in subgingival
plaque. These observations might be partly explained by
the antimicrobial activity of fatty acid esters of sucrose and
glycerol [28, 29], which were added as lubricants to both the
test and control tablet. Another possible explanation relates
to an attention bias (Hawthorne eﬀect) occurred within
subjects in this study [30, 31]. Our results indicated that
PCR scores and total bacterial counts had a tendency to
decrease in both groups, although the experimental protocol
did not include any oral hygiene instruction before or at
baseline.Ithasbeendocumentedthatmanyfactorsincluding
attention bias contributed to perceived placebo eﬀects in
large-scale, randomized, controlled trials [31]. Furthermore,
arecentstudysuggestedthatoraladministrationofthetablet6 International Journal of Dentistry
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Figure 3:Eﬀectsofthetesttabletonbacterialnumberandendotoxinlevelsinsaliva,subgingivalplaque,andgingivalcrevicularﬂuid(GCF).
Total bacterial number in saliva (a), total bacterial number in subgingival plaque (b), P. gingivalis number in saliva (c), P. gingivalis number
in subgingival plaque (d), saliva levels of endotoxin (e), and GCF levels of endotoxin (f) were measured at baseline, 1W, 4W, 12W. Values
represent the mean ± standard error. The number of total bacteria and P. gingivalis in subgingival plaque and GCF levels of endotoxin were
assessed in two teeth with chronic periodontitis per subject.∗Signiﬁcant diﬀerence between the test and control groups, as identiﬁed by
Student’s t-test (P<. 05).International Journal of Dentistry 7
Table 2: Eﬀects of bovine LF and LPO-containing tablets on clinical periodontal parameters.
Parameter Group (n) Baseline 1 Week 4 Weeks 12 Weeks
PCR Test (37) 58.33 ±2.15 55.14 ±1.80 52.36 ±1.94 50.53 ± 2.29
Control (35) 58.70 ±2.09 58.43 ±1.99 54.69 ±2.40 53.69 ± 2.50
PlI Test (74) 1.12 ±0.04 1.01 ±0.01 1.03 ±0.03 1.04 ±0.04
Control (70) 1.04 ±0.02 1.07 ±0.03 1.01 ±0.03 1.06 ±0.03
GI Test (74) 1.54 ±0.06 1.39 ±0.06 1.41 ±0.06 1.34 ±0.06
Control (70) 1.47 ±0.06 1.30 ±0.06 1.37 ±0.06 1.34 ±0.06
BOP Test (74) 56.76 ±5.80 40.54 ±5.75 40.54 ±5.75 36.49 ± 5.63
Control (70) 50.00 ±6.02 32.86 ±5.65 41.43 ±5.93 34.29 ± 5.71
PD Test (74) 4.97 ±0.14 4.69 ±0.11 4.58 ±0.10 4.16 ±0.09
Control (70) 4.60 ±0.09 4.49 ±0.09 4.36 ±0.07 4.04 ±0.09
CAL Test (74) 4.97 ±0.14 4.69 ±0.11 4.58 ±0.10 4.18 ±0.09
Control (70) 4.60 ±0.09 4.49 ±0.09 4.36 ±0.07 4.04 ±0.09
Values represent the mean ± standard error.
PCR: plaque control record (%). PlI: plaque index. GI: gingival index. BOP: bleeding on probing (%). PD: probing depth (mm). CAL: clinical attachment
level (mm).
PlI, GI, BOP, PD, and CAL were assessed in two teeth with chronic periodontitis per subject.
itself may stimulate secretion of saliva, possibly aﬀecting
periodontal condition [32].
Apart from bovine LF and LPO, there were also
diﬀerences in the contents between the test and control
tablet. Glucose oxidase and glucose were added in the
test tablet, leading to generation of hydrogen peroxide
necessary for the LPO system [33]. Likewise, trisodium
citrate dehydrate and citric acid were included as buﬀer
salts into the test tablet to make the solvent a slightly
acid, resulting in an optimal condition for the enzymatic
activity of LPO. The test tablet also contains sugar alcohols
such as xylitol and erythritol. These sugar alcohols were
reported to exhibit a potential suppressive eﬀect on bioﬁlm
formation in vitro [34–36], implicating some eﬀects on
periodontal condition. However, the concentrations of these
sugar alcohols used for the test tablet were much lower
than those reported in the studies [29, 37, 38]. Therefore,
it is conceivable that the aforementioned components of
the tablet would not inﬂuence clinical and bacteriological
proﬁles.
We performed both the individual and site analysis in
this study, for better understanding of the eﬃcacy of the
test tablets on periodontal parameters, levels of subgingival
plaque bacteria, and bovine and human LF and endotoxin in
gingival crevicular ﬂuid (GCF) in the periodontally diseased
site. However, the site analysis was performed in either the
individual site or tooth chosen, which may be inﬂuenced by
the patient’s individual characteristics. Therefore, it might be
necessary when interpreting our results with the caution.
LF and LPO are component of saliva, and were puriﬁed
from bovine milk for the test tablet. Other components of
thetesttabletarealsosafeinhealth.Allofthesecompositions
havebeenpermittedtobeincludedincommerciallyavailable
food and drink in Japan. Our results demonstrated that
oral administration of these tablets showed no abnormal
adverse events in general and oral condition. Therefore, it is
expected that bovine LF and LPO-containing tablet would
be used more safely, rather than the commercially available
antiinfective products.
5. Conclusions
The results of our clinical study suggest that the eﬀect of oral
administration of LF and LPO-containing tablets might be
weak on periodontal and bacteriological proﬁle.
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